<DOC>
	<DOCNO>NCT01863888</DOCNO>
	<brief_summary>Primary Objective : To measure effect Teriflunomide lymphocytes subset patient relapse form multiple sclerosis compare baseline value reference population untreated healthy subject . Secondary Objectives : To assess Teriflunomide treatment result bias T cell clonal diversity . To assess effect Teriflunomide function peripheral blood mononuclear cell ( proliferation cytokine production situ ) . To assess circulate cytokine profile serum Relapsing Multiple Sclerosis ( RMS ) patient 24-week treatment versus baseline healthy control . To assess reversibility parameter change patient discontinue treatment accelerate elimination procedure cholestyramine activate charcoal .</brief_summary>
	<brief_title>Effect Teriflunomide Immune Cell Subsets Blood Patients With Multiple Sclerosis</brief_title>
	<detailed_description>The duration study patient 32 week include 4 week screen , 24 week treatment 4 week follow-up . An extension study propose Teriflunomide commercially available country patient life . The duration study healthy volunteer 25 week include one week screening .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Cholestyramine Resin</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Inclusion criterion : Patients ( male female ) relapse form multiple sclerosis meeting McDonald criterion MS screen visit either one follow treatment status : Naïve disease modifying ( DM ) treatment DM treatment 2 year Or currently ( 3 month interruption ) MS therapy IFN β1 Glatiramer acetate period least 2 week without IFN β1 Glatiramer acetate switch teriflunomide . Male female patient , 18 56 year age , exclusive . Healthy volunteer : Male female subject , 18 56 year age , exclusive . Body weight 50.0 95.0 kg , inclusive , male ; 40.0 85.0 kg , inclusive , female , body mass index 18.0 30.0 kg/m2 , inclusive . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . Normal vital sign 10 minute rest supine position : 95 mmHg &lt; systolic blood pressure ( SBP ) &lt; 140 mmHg 45 mmHg &lt; diastolic blood pressure ( DBP ) &lt; 90 mmHg 40 bpm &lt; heart rate ( HR ) &lt; 100 bpm Normal standard 12lead electrocardiogram ( ECG ) 10 minute rest supine position ; 120 m &lt; PR &lt; 220 m , QRS &lt; 120 m , QTc ≤ 430 m male , ≤ 450 m female . Laboratory parameter within normal range ( define screen threshold Investigator site ) , unless Investigator considers abnormality clinically irrelevant healthy subject ; however liver function parameter ( ) exceed upper laboratory norm . Exclusion criterion : Did consent HIV test ( specific inform consent process HIV test do accordance local guideline ) . A relapse within 30 day prior screen . Clinically relevant cardiovascular , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult would put patient risk participate study . Patients congenital acquire severe immunodeficiency , history cancer ( except basal squamous cell skin lesion surgically excise , evidence metastasis ) , lymphoproliferative disease , patient receive lymphoid irradiation . Human immunodeficiency virus ( HIV ) positive patient . Known history active tuberculosis adequately treat positive QuantiFERON TB Gold test . Hypoproteinemia ( eg , case severe liver disease nephrotic syndrome ) serum albumin &lt; 3.0 g/dL . Moderate severe impairment renal function , show serum creatinine &gt; 133 μmol/L ( &gt; 1.5 mg/dL ) . Patients significantly impair bone marrow function significant anemia , leukopenia , thrombocytopenia . Acute chronic infection . Liver function impairment persist elevation &gt; 1.5ULN ( confirm retest ) serum glutamic pyruvic transaminase/ alanine aminotransferase ( SGPT/ALT ) , serum glutamic oxaloacetic transaminase/aspartate aminotransferase ( SGOT/AST ) , direct bilirubin great 1.5fold upper limit normal . Use adrenocorticotrophic hormone ( ACTH ) systemic corticosteroid 2 week prior screen . Prior concomitant use cytokine therapy intravenous immunoglobulin 3 month prior screen . Prior use alemtuzumab cladribine . Prior use ( within 1 year ) fingolimod ( Gylenia® ) . Prior use ( within 2 year ) mitoxantrone , natalizumab ( Tysabri® ) , immunosuppressant agent ( i.e . azathioprine , cyclophosphamide , cyclosporin , methotrexate mycophenolate ) . Prior treatment teriflunomide , prior concomitant use leflunomide ( ARAVA® ) hypersensitivity ingredient excipients investigational product . Prior use investigational drug 6 month precede screen . Pregnant breastfeed woman . Women childbearing potential utilizing effective contraceptive method /or woman childbearing potential unwilling unable test pregnancy . Known history hypersensitivity teriflunomide leflunomide . Persisting elevation ( confirm retest ) serum amylase lipase great 2fold upper limit normal . Known history chronic pancreatic disease pancreatitis . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>